

[coat of arms of the Republic of Serbia]

Republic of Serbia
MINISTRY OF HEALTH
Number: 515-04-05458/2019-11
Date: 05 May 2020
Belgrade, 22-26 Nemanjina St.
Tel 26 00 749
JPM/JV

Acting upon the request of pharmaceutical manufacturer 'HEMOFARM' a.d. Vršac, for issuing the Good Manufacturing Practice certificate and pursuant to the Article 212, paragraph 6 of the Law on Medicines and Medical Devices ('Official Gazette of RS' No. 30/10, 107/12, 105/17 – st. law and 113/2017 – st. law), Article 136 of the Law on General Administrative Procedure ('Official Gazette of the Republic of Serbia' No. 18/16) the Minister of Health of the Republic of Serbia passes the following

DECISION

1. **Good Manufacturing Practice CERTIFICATE NUMBER 30 IS ISSUED** to the pharmaceutical manufacturer '**HEMOFARM**' a.d. Vršac, Beogradski put bb, for **the manufacturing, quality control and batch release site** '**HEMOFARM**' a.d. Vršac, Beogradski put bb.
2. This Certificate is valid for the indicated manufacturing site by **28th January 2023**, after which time its validity is terminated.

Rationale

The pharmaceutical manufacturer 'HEMOFARM' a.d. Vršac filed a request to the Ministry of Health for issuing the Good Manufacturing Practice certificate for the manufacturing site in Vršac, Beogradski put bb for:

1. **Manufacture in the Sterile Products Plant, SPP** (the overall procedure): 1) Infusion Solutions Department – *Large volume sterile liquid pharmaceutical forms (infusions), terminally sterilized* as follows: Glucosi infundibile, infusion solution, 5%, plastic bottle, 1x500 ml; Glucosi infundibile, infusion solution, 10%, plastic bottle, 1x500ml; Hartmann's solution, infusion solution, 6.02 g/L+0.373 g/L + 0.294 g/L + 6.276 g/L, bottle, 1x500ml; Natrii chloridi infundibile, infusion solution, 9g/L, plastic bottle, 1x500ml; Natrii chloridi infundibile compositum (Ringer's solution), infusion solution, 8.6g/L+0.3g/L+0.33g/L, plastic bottle, 1x500ml; Natrii chloridi infundibile cum Glucoso 5%, infusion solution, 1x500ml; 2) Lyophilizates Department – *Sterile liquid pharmaceutical forms – aseptically prepared lyophilized forms* as follows: Phenobarbital sodium, powder and solvent for injection solution, 220mg/2ml, bottle with powder and ampoule with solvent, 5x2ml; Hydrocortisone, lyophilizate for solution for injection with the solvent for parenteral use, 100mg/2ml, lyo-vial with a solvent in ampoule, 1x2ml; Lemod-Solu, powder and solvent for solution for injection/infusion, 20mg/ml, lyo-vial with solvent in ampoule, 15x1ml; Lemod-Solu, powder and solvent for injection/infusion solution, 40mg/ml, lyo-vial with



solvent in ampoule, 15x1 ml; Peptix®, powder for injection/infusion solution, 40 mg/5 ml, vial, 10x40mg; Hemomycin®, powder for concentrate for infusion solution, 500mg, vial, 1x500mg; (manufacture in Injectables Plant, secondary packaging in Sterile Products Plant); Hydrocortisone, lyophilizate for solution for injection with the solvent for parenteral use, 100mg/2ml, lyo-vial with solvent in ampoule, 1x2ml; (manufacture Injectables Plant, secondary packaging Sterile Products Plant); Beviplex® powder for solution for injection; 40mg+4mg+8mg+100mg+10mg+0.004mg; glass bottle, up to the 'bulk' phase (for contract manufacturer 'Galenika' A.D. Beograd); 3) Injectables Department – Aseptically prepared small volume sterile liquid pharmaceutical forms, as follows: Diklofenak, injection solution, 75mg/3ml, ampoule, 5x3ml; Nirmin®, concentrate for infusion solution, 5mg/1.6ml, ampoule, 50x1.6ml, (visual inspection and packaging in Injectables Plant); Marocen®, concentrate for infusion solution, 100mg/10ml, ampoule, 5x10ml (visual inspection and integrity test only); Ranitidin, injection/infusion solution, 50mg/2ml, ampoule, 5x2ml, Water for injection with 0.9% of benzyl alcohol, ampoule, 1ml; Water for injection with 0.9% of benzyl alcohol, ampoule, 2 ml; Water for injection with 0.9% of benzyl alcohol, ampoule, 7.8ml (visual inspection and integrity test only); Aqua redestilata, injection solvent, ampoule 2 ml;

2. **Manufacture in the Injectables Plant, IP** (overall procedure): 1) Injectable Solutions Department – (1) Aseptically prepared small volume sterile liquid pharmaceutical forms as follows: Diklofenak, injection solution, 75mg/3ml, ampoule, 5x3ml; Methylegometrin, injection solution, 0.1mg/ml, ampoule, 50x1ml; Methylegometrin, injection solution, 0.2 mg/ml, ampoule, 50x1ml; Klindamicin, injection solution, 300mg/2ml, ampoule, 10x2ml; Gentamicin, injection solution, 80mg/2ml, ampoule, 10x2ml; Gentamicin, injection solution, 120mg/2ml, ampoule, 10x2ml; Nirmin®, concentrate for infusion solution, 5mg/1.6ml, ampoule, 50x1.6ml, (visual inspection and packaging); Marocen, concentrate for infusion solution, 100mg/10ml, ampoule, 5x10ml (visual inspection and integrity test in Sterile Products Plant); Ranitidin, solution for injection/infusion, 50mg/2ml, ampoule, 5x2ml, Water for injection with 0.9% of benzyl alcohol, ampoule, 1ml; Water for injection with 0.9% of benzyl alcohol, ampoule, 2 ml; Water for injection with 0.9% of benzyl alcohol, ampoule, 7.8ml (visual inspection and integrity test in Sterile Products Plant); Aqua redestilata, injection solvent, ampoule 2ml; 2) Small volume sterile liquid pharmaceutical forms terminally sterilized as follows: Trodon, injectable solution, 100mg/2mL, ampoule, 5x2mL; Trodon, injectable solution, 50mg/mL, ampoule, 5x1mL; Presolol, injectable solution, 5mg/5mL, ampoule, 5x5mL; 2) Lyophilized Products Department – Sterile liquid pharmaceutical forms – aseptically prepared lyophilized forms, as follows: Hemomycin®, powder for infusion solution, 500mg, vial, 1x500mg; Hidrokortizon, lyophilizate for injection solution with solvent for parenteral use, 100mg/2ml, lyo-vial with solvent in ampoule, 1x2ml; Lemod-Solu, powder and solvent for injection/infusion solution, 20mg/ml, lyo-vial with solvent in ampoule, 15x1ml; Lemod-Solu, powder and solvent for injection/infusion solution, 40mg/ml, lyo-vial with solvent in ampoule, 15x1ml; Lemod-Solu, powder and solvent for injection/infusion solution, 125mg/2ml, lyo-vial with solvent in ampoule, 1x2ml; Lemod-Solu, powder and solvent for solution for injection/infusion, 500mg/7.8ml, lyo-vial with solvent in ampoule, 1x7.8ml;



3. **Manufacture in the Sterile Products Plant, SPP** – part of the manufacturing procedure – secondary packaging of medicines as follows: EQRALYS, injection solution in the pre-filled injection syringe, 1000 IU/0.3 ml, 6x0.3ml; EQRALYS, injection solution in the pre-filled syringe, 2000 IU/0.6 ml, 6x0.6ml; EQRALYS, injection solution in the pre-filled syringe, 4000 IU/0.4 ml, 6x0.4ml; EQRALYS, injection solution in the pre-filled syringe, 10000 IU/1ml, 1x1ml; EQRALYS, injection solution in the pre-filled syringe, 20000 IU/0.5ml, 1x0.5ml; EQRALYS, injection solution in the pre-filled syringe, 30000 IU/0.75ml, 1x0.75ml; Ademola (Voriconazole), powder for infusion solution, 200mg, vial, 1x200mg; Zodal, injection solution, 30mg/ml, ampoule, 5x1ml; Corpos® (ocrelizumab) concentrate for infusion solution, 300 mg/10ml, glass vial, 1x10ml.

In the period from 27/01 to 29/01/2020, the inspectors for medicines and medical devices, pursuant to Article 208 and 213, paragraph 1, item 1 of the Law on Medicines and Medical Devices ('Official Gazette of Republic of Serbia, No. 30/10, 107/12, 105/17 – st. law and 113/17-st. law), and the Rule Book on Conditions for Manufacture of Medicines, Content of the Pharmaceutical Licence Form and Register of Issued Pharmaceutical Licences ('Official Gazette of Republic of Serbia', No. 18/12) performed the inspection at the manufacturing site 'HEMOFARM' a.d. Vršac, Beogradski put bb (Sterile Products Plant and Injectables Plant) for the purpose of establishing the compliance of the pharmaceutical manufacture – liquid sterile pharmaceutical forms and lyophilizates with the Good Manufacturing Practice guidelines ('Official Gazette of Republic of Serbia', No. 97/17), about which a protocol No. 515-04-5458/2020-11 of 06/04/2020 was made. There were no objections of the manufacturer to the factual status established in the protocol.

The subject of establishing the compliance of the manufacture with the Good Manufacturing Practice guidelines referred to production processes, quality control and release of medicines indicated in the application for sale.

Based on the directly established factual state, as well as after having inspected the documentation during the inspection control, it was established that the manufacture of the above indicated medicines was in compliance with the Good Manufacturing Practice guidelines, about which the final report was made, containing the conclusion on compliance, number 515-04-05458-1/2020-11 of 04/05/2020, which was delivered to the manufacturer.

Based on the Final Report number 515-04-05458-1/2020-11 of 04/05/2020 and in line with Article 113, paragraph 7, of the Law on Medicines and Medical Devices, it has been decided as in Item 1 of the wording of this decision.

Pharmaceutical manufacturer is responsible for the quality of manufactured medicines in line with Article 111 of the Law on Medicines and Medical Devices.

Pursuant to Article 114, paragraph 5, of the Law on Medicines and Medical Devices, it has been decided as in Item 2 of the wording of this decision.

This decision is final in the administrative procedure.

Administrative dispute can be instigated against this decision before the competent court within 30 days from the receipt of this decision.

The applicant has paid the fee for this decision based on the Law on Republic Administrative Fees ('Official Gazette of RS', no. 38/19).

Distribution:

1. 'HEMOFARM' a.d. Vršac
Vršac, Beogradski put bb
2. Archives

MINISTER

Dr Zlatibor Lončar

/stamped and signed/

/stamp reading: Republic of Serbia, Ministry of Health,



**GOOD MANUFACTURING PRACTICE CERTIFICATE
(GMP CERTIFICATE)**

Certificate No.:	30
Date:	5 th May 2020

Name of manufacturing license holder (pharmaceutical manufacturer):	'HEMOFARM' AD Vršac
Address of manufacturing license holder (pharmaceutical manufacturer) seat:	Vršac, Beogradski put, bb
Address of manufacturing site:	'HEMOFARM' AD Vršac Vršac, Beogradski put, bb
Medicine batch release site:	'HEMOFARM' AD Vršac Vršac Beogradski put bb
Legal grounds for issuing the certificate:	Article 114 of the Law on Medicines and Medical Devices ('Official Gazette of RS', No. 30/10, 107/12, 105/17 – st. law and 113/17 – st. law)
Date of inspection based on which the certificate is issued:	from 27/01/2020 to 29/01/2020
Validity of certificate:	Good Manufacturing Practice Certificate is issued for a three-year period and its validity is terminated in case of manufacturing process changes or a change in quality control and batch release of a particular pharmaceutical form specified in the certificate.



Pharmaceutical Manufacturer '**HEMOFARM**' AD VRŠAC, Vršac, Beogradski put bb, which has been issued the **pharmaceutical manufacturing license** number 515-04-07558/2019-11 of 8th November 2019, is hereby issued a **Good Manufacturing Practice Certificate for the manufacturing site** - '**HEMOFARM**' AD VRŠAC, Vršac, Beogradski put bb.

☒ on the basis of the inspection of pharmaceutical manufacturing site, conducted in accordance with Article 213 of the Law on Medicines and Medical Devices ('Official Gazette of RS', no. 30/10, 107/12, 105/17 – st. law and 113/17 – st. law), and the Final Report no. 515-04-05458-1/2019-11 of 28/04/2020 on compliance of pharmaceutical manufacturing with the Good Manufacturing Practice Guidelines ('Official Gazette of RS', number 97/17),

☐ on the basis of the inspection of the manufacturer the medicine of which is in the process of obtaining authorisation, amendments or addenda, i.e. renewal of a marketing authorisation in the Republic of Serbia, conducted in accordance with Article 215 of the Law on Medicines and Medical Devices ('Official Gazette of RS', no. 30/10, 107/12, 105/17 – st. law and 113/17 – st. law), and the Final Report numberdated on compliance of manufacturing with the Good Manufacturing Practice Guidelines ('Official Gazette of RS', no. 97/17),

☐ on the basis of the inspection of the active substance manufacturing at the pharmaceutical manufacturing site, conducted in accordance with Article 112, paragraph 3, of the Law on Medicines and Medical Devices ('Official Gazette of RS', no. 30/10, 107/12, 105/17 – st. law and 113/17 – st. law).

This Certificate confirms the compliance of the pharmaceutical manufacture with the Good Manufacturing Practice Guidelines on the day of inspection.

Distribution:

1. '**HEMOFARM**' a.d. Vršac
Vršac, Beogradski put bb
2. Archives

MINISTER
Dr Zlatibor Lončar
/stamped and signed/



Annex 1

BASIC INFORMATION (to be filled out in capital letters)	
Manufacture of the following types of medicines:	☒ medicines ☐ immunological medicines ☐ medicines from blood and blood plasma of human origin ☐ biotechnological medicines ☐ radiopharmaceutical medicines ☐ herbal medicines ☐ medicines indented for clinical studies ☐ other types of medicines
Manufacture of medicines which contain controlled psychoactive substances:	☒ yes ☐ no



Annex 2

Approved pharmaceutical manufacturing processes, i.e. procedures	
☒ 1. Sterile manufacture	☒ 1.1 Aseptic preparation ☒ 1.2 Terminal sterilization ☐ 1.3 Actual medicine batch release
☐ 2. Manufacture of non-sterile pharmaceutical products	☐ 2.1 Solid pharmaceutical forms ☐ 2.2 Semi-solid pharmaceutical forms ☐ 2.3 Liquid pharmaceutical forms ☐ 2.4 Other ☐ 2.5 Actual medicine batch release
☐ 3. Manufacture of biological medicines	☐ 3.1 Medicines from human blood and plasma ☐ 3.2 Immunological medicines ☐ 3.3 Biotechnological medicines ☐ 3.4 Extracts of human or animal origin ☐ 3.5 Actual medicine batch release
☒ 4. Packaging	☒ 4.1 Primary packaging ☒ 4.2 Secondary packaging
☒ 5. Quality control	☒ 5.1 Own control laboratory ☐ 5.2 Contract control laboratory
☒ 6. Manner of supply with active substances and intermediates (<i>bulk</i> products)	☐ 6.1 Own manufacture ☐ 6.2 Market of the Republic of Serbia ☒ 6.3 Import



Annex 3

Remarks, i.e. additional explanations regarding the content of the certificate:

This certificate on compliance of pharmaceutical manufacturing with the Good Manufacturing Practice Guidelines refers to: 1) manufacturing of liquid sterile pharmaceutical forms (procedure of terminal sterilization and aseptic procedure) and lyophilizates (aseptic procedure) which are manufactured at this manufacturing site (Sterile Products Plant and Injectables Plant) as the overall manufacturing procedure; 2) a part of the manufacturing procedure – secondary packaging of medicines – sterile liquid pharmaceutical forms, as well as to the quality control and release of manufactured batches of medicine for sale.

-----end of translation-----

I hereby certify by my seal and signature that the above translation is in full conformity with the original document presented to me in the Serbian language.

SNEŽANA KREČAK, Permanent Sworn-in Court Translator for the English language appointed by the Decision of the Regional Secretariat for Education, Governance and National Communities of the Autonomous Province Vojvodina No. 128-74-54/2011 of 30/03/2012.

